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Introduction  64 
 65 
The physiology and clinical utility of anti-Müllerian hormone (AMH) are not completely established. 66 
However, because of the tremendous amount of data collected in recent years, it appeared timely for 67 
this group of experts to bring together the current knowledge. These experts met in Lille, France, in May 68 
2012 for an ESHRE Campus workshop. This review offers a structured proceeding of this workshop that 69 
has been updated with the most recent data published in the literature since then. Its aim is to provide 70 
an extensive overview of the current knowledge and position of AMH as a tool in female health and 71 
fertility care. While covering most aspects of the physiology and utility of AMH, some aspects (e.g., use 72 
in diagnosis of granulosa cell tumours) were not covered, but are discussed in excellent reviews (e.g., La 73 
Marca et al., 2007). 74 
 75 
Historical perspective and state of the art 76 
 77 
AMH is a dimeric glycoprotein and a member of the transforming growth factor β (TGF-β) family of 78 
growth and differentiation factors (Cate et al., 1986). AMH has been predominantly known for its role in 79 
male sexual differentiation. From castration experiments in the fetal rabbit, Jost demonstrated that a 80 
testicular factor distinct from testosterone was responsible for the regression of the Müllerian ducts 81 
during male fetal sex differentiation (Jost, 1947). In later years, it was demonstrated that this factor is 82 
produced by Sertoli cells in the testis (Josso et al., 1993).  83 
The ovary is also able to produce AMH. In the chicken, this occurs from early embryonic development to 84 
adulthood (Hutson et al., 1981) but in human, AMH production by granulosa cells was detected only at 85 
the end of gestation (Rajpert-De Meyts et al., 1999). Interest into the role of AMH in the female was 86 
principally evoked through studies of AMH-deficient mice. Although female mice appeared fertile in the 87 
absence of AMH (Behringer et al., 1994), more detailed analysis of the ovarian follicle pool revealed that 88 
AMH acted as an inhibitor of primordial follicle recruitment. Also, later studies demonstrated a potential 89 
role for AMH in dominant follicle selection in the follicular phase of the menstrual cycle (Visser and 90 
Themmen, 2005). The development of sensitive assays soon enabled measuring AMH in serum (Hudson 91 
et al., 1990; Josso et al., 1990; Baker et al., 1990). Release of AMH from the granulosa cells of antral 92 
follicles leads to measurable serum levels, and these concentrations have shown to be proportional to 93 
the number of developing follicles in the ovaries. Therefore, AMH was considered to be a marker for the 94 
process of ovarian ageing (Kevenaar et al., 2006).  95 
To date, AMH has developed into a factor with a wide array of clinical applications, mainly based on its 96 
ability to express the number of antral and pre-antral follicles present in the ovaries (Hansen et al., 97 
2011). Predicting ovarian response to hyperstimulation of the ovaries for IVF, with the possibility of 98 
individualized counseling and adjustments of the stimulation regimen, is the most appealing application 99 
under development so far. Assessment of damage to the ovarian follicle reserve inflicted by iatrogenic 100 
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sources such as pelvic irradiation, chemotherapy, uterine artery embolization or ovarian surgery using 101 
AMH may open avenues of choosing strategies to prevent this damage in selected cases by applying 102 
fertility preservation strategies. The emerging data on the relation between AMH level at a certain age 103 
and the timing of menopause has set a scene for an individualized prediction of the reproductive 104 
lifespan, and from there potential prevention of infertility based on early ovarian ageing. Finally, 105 
marking the excess of antral follicles in women with Polycystic Ovarian Syndrome (PCOS), AMH may 106 
soon replace the ultrasound ovarian morphology criterion in the diagnosis of this syndrome, as well as 107 
become an additional tool for diagnosing premature ovarian insufficiency (POI).  108 
Physiology 109 
The roles of AMH in ovarian physiology 110 
 111 
AMH is specifically expressed in granulosa cells of small growing follicles. In rodents, expression is 112 
initiated as soon as primordial follicles are recruited to grow, and highest expression is observed in 113 
preantral and small antral follicles. AMH is no longer expressed by mural granulosa cells during the FSH-114 
dependent stages of follicular growth, nor is it expressed in atretic follicles (reviewed in Durlinger et al., 115 
2002). However, expression persists in the cumulus cells of preovulatory follicles (Salmon et al., 2004). In 116 
the human ovary, AMH shows a very similar expression pattern (Rey et al., 2000; Weenen et al., 2004; 117 
Grondahl et al., 2011; Jeppesen et al., 2013). 118 
Functional roles of AMH in ovarian folliculogenesis were revealed by analysis of the follicle pool in 119 
ovaries of AMH-deficient mice at various ages. In the absence of AMH, primordial follicles are recruited 120 
at a faster rate, resulting in an exhausted primordial follicle pool at a younger age (Durlinger et al., 121 
1999). The inhibitory effect of AMH on primordial to primary follicle transition was confirmed by in vitro 122 
studies of neonatal ovaries and ovarian cortical strips of various species, including human (Durlinger et 123 
al., 2002; Nilsson et al., 2007; Gigli et al., 2005; Carlsson et al., 2006). However, contradictory results 124 
using human ovarian cortical tissue have also been reported (Schmidt et al., 2005). In the mouse AMH 125 
inhibited the effect of several growth factors known to have a stimulatory action on primordial follicle 126 
recruitment, such as KitL and bFGF (Nilsson, et al., 2007). In the absence of AMH, ovaries contain more 127 
growing follicles, yet AMH-deficient mice have a normal ovulation rate. Increased oocyte degeneration 128 
and follicular atresia suggests that AMH may also be a survival factor for small growing follicles (Visser et 129 
al., 2007). AMH also reduces follicle sensitivity to FSH in vivo, and in vitro AMH inhibited FSH-induced 130 
preantral follicle growth (Durlinger et al., 2001). Thus, there is clear evidence that AMH is involved in the 131 
regulation of follicle growth initiation and the threshold for FSH sensitivity (Figure 1).  132 
AMH has also been suggested to exert a physiological effect on antral follicles in the human ovary 133 
before final selection. There exists a fine-tuned and delicate balance between estradiol (and inhibin) 134 
output by the preovulatory follicle and gonadotrophin secretion by the pituitary to ensure that ovulation 135 
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is triggered exactly at the right time (Baird and Smith, 1993). Recently, it has been suggested that AMH 136 
may exert a physiological role in down regulating the aromatizing capacity of granulosa cells until the 137 
time of follicular selection (Figure 1). Several studies have shown that AMH expression remains high 138 
until a follicle reaches a diameter of around 8mm (Weenen, et al., 2004, Andersen et al., 2010, 139 
Jeppesen, et al., 2013). The intrafollicular concentrations of AMH in normal human antral follicles show 140 
a gradual reduction as the diameter of the follicle increases, and a sharp decline is observed around 141 
8mm (Andersen, et al., 2010). The rapid decline in AMH expression corresponds with the selection of 142 
follicles for dominance, which is characterized by a transition from a low-estrogen producing state to 143 
one of rapidly increasing estrogen production. Estradiol is instrumental in this decline through estradiol 144 
receptor , which interacts with the AMH promoter region (Grynberg et al., 2012) (Figure 1). 145 
Several lines of evidence suggest that AMH acts as gatekeeper of follicular estrogen production:  146 
1) Early studies on fetal ovine ovaries showed that AMH repressed aromatase biosynthesis (Vigier 147 
et al., 1989). A quantitative bioassay for AMH was subsequently developed based on inhibition 148 
of cAMP-induced aromatase activity in fetal rat ovaries (di Clemente et al., 1992).  149 
2) In granulosa-lutein cells from IVF patients AMH reduces the expression of CYP19a1 at both gene 150 
and protein level and FSH-induced E2 production was significantly reduced in the presence of 151 
AMH (Grossman et al., 2008). 152 
3) In human small antral follicles there is a distinct inverse association between intrafollicular 153 
concentrations of AMH and estradiol concentrations and CYP19a1 gene expression in the 154 
corresponding granulosa cells (Andersen and Byskov, 2006, Andersen and Lossl, 2008, Nielsen et 155 
al., 2011). 156 
4) Using adjacent ovarian sections of preovulatory sheep follicles it was observed that the oocyte 157 
cumulus complex showed an almost complete inverse expression pattern of AMH and 158 
aromatase (Campbell et al., 2012). AMH continues to be expressed in cumulus cells of 159 
preovulatory follicles in the human (Grondahl, et al., 2011). 160 
5) Association analysis of genetic variants of the AMH signaling pathway showed that the AMH 161 
Ile49Ser and AMH type 2 receptor (AMHR2) -482A>G variants were related to follicular-phase 162 
estradiol levels in normo-ovulatory women. Women carrying the minor allele of the AMH or the 163 
AMHR2 polymorphism had higher estradiol levels compared to non-carriers, with carriers of 164 
both minor alleles having the highest levels (Kevenaar et al., 2007). In vitro, the AMH 49Ser 165 
variant yields a less active AMH protein that could result in weaker inhibition of FSH-induced 166 
aromatase activity and follicle growth (Kevenaar et al., 2008).  167 
Thus, AMH may act as a follicular gatekeeper and ensure that each small antral follicle produces little 168 
estradiol prior to selection (i.e. up to a follicular diameter of approximately 8mm) allowing a direct 169 
ovarian/pituitary dialogue regulating the development of the selected follicle that will undergo 170 
ovulation (Jeppesen, et al., 2013) (Figure 1).  171 
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 Assessment of AMH in serum: assay development 172 
AMH is produced as a precursor protein, consisting of 70 kDa disulphide-linked monomers (Picard and 173 
Josso, 1984). Proteolytic processing yields a 55 kDa N-terminal proregion and a 12.5 kDa C-terminal 174 
mature region (Pepinsky et al., 1988, Nachtigal and Ingraham, 1996). The pro- and mature homodimers 175 
remain non-covalently associated, resulting in a 140 kDa complex in circulation (Lee and Donahoe, 1993) 176 
(Figure 2). The mature region of AMH holds the biological activity of the protein, but in contrast to other 177 
TGFβ family members, requires the N-terminal proregion to obtain its full activity (Wilson, 1993). It has 178 
been suggested that the proregion is involved in protein stability and folding (Belville et al., 2004).  179 
Measurement of serum AMH was first reported in the 1990s, with the development of three AMH 180 
enzyme-linked immunosorbent assays (ELISAs) (Baker et al., 1990; Hudson, et al., 1990; Josso et al., 181 
1990). The AMH ELISAs were initially developed to measure AMH as a marker for testicular function 182 
during childhood, when serum concentrations are much higher than in females. Using a monoclonal and 183 
a polyclonal antibody that were both raised against recombinant human AMH (rhAMH), and which both 184 
recognize epitopes in the proregion of AMH, a sensitivity of 0.5 ng/ml was reached (Hudson, et al., 185 
1990). Baker et al developed an assay with antibodies raised against bovine AMH and rhAMH, but this 186 
assay was unable to detect AMH in female serum samples because of the relatively high detection limit 187 
of 6.25 ng/ml and the presence of inhibitory effects of serum. The assay developed by Josso and 188 
colleagues used a single polyclonal antibody raised against purified bovine AMH with rhAMH as the 189 
standard (Josso, et al., 1990). In this assay, the minimal detectable dose of AMH was 0.02 ng. This assay 190 
was subsequently modified to a sandwich ELISA using a monoclonal and polyclonal antibody raised 191 
against rhAMH. These antibodies recognize epitopes in the pro- and mature region of AMH (Figure 2), 192 
and increased the sensitivity of the assay to 14 pmol/L (1 ng/ml = 7.14 pmol/L) (Carre-Eusebe et al., 193 
1992). A further improvement in sensitivity to 0.7 pmol/L was reached by the use of two different 194 
monoclonal antibodies (Long et al., 2000). This ultrasensitive assay, known as the IOT assay, became 195 
commercially available through Beckman-Coulter (originally Immunotech-Coulter). 196 
The importance of assessment of serum AMH levels in females followed the insight (based on the 197 
expression pattern) that serum AMH might be a proxy for the size of the primordial follicle pool 198 
(reviewed in Visser et al., 2006). This led to the development of an additional sensitive AMH ELISA. 199 
Highly specific monoclonal antibodies to the proregion of AMH were generated by immunization of 200 
female AMH-deficient mice with rhAMH (Al-Qahtani et al., 2005). These antibodies had different 201 
epitope specificities and, with rhAMH as the standard, the detection limit improved to 0.078 ng/ml (Al-202 
Qahtani, et al., 2005). This assay was subsequently improved with another pair of highly specific 203 
monoclonal antibodies, which recognize epitopes in both the proregion (F2B/7A) and mature regions 204 
(F2B/12H) (Kevenaar, et al., 2006) (Figure 2). This assay is therefore expected to measure total AMH, 205 
and was commercially available through Diagnostic Systems Lab (DSL), has a detection limit of 6.3 pg/ml 206 
(Kevenaar, et al., 2006). 207 
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With the availability of two commercial assays, research on the clinical application of serum AMH 208 
increased tremendously. However, because these assays use different antibody pairs, and even more 209 
importantly different AMH calibrators, values of serum AMH differed significantly between the assays 210 
being 3- to 4- fold lower in the DSL assay (Freour et al., 2007). In later publications, similar AMH values 211 
were reported for both assays (Streuli et al., 2009, Lee et al., 2011), indicating that the assays continued 212 
to evolve. This may, in part, explain the different conversion factors that have been reported in various 213 
studies (Hehenkamp et al., 2006, Freour, et al., 2007). As a consequence, values obtained by one assay 214 
may not be directly translated to results obtained with the other assay.  215 
With the acquisition of DSL by Beckman-Coulter, the two existing assays were replaced by a new ELISA. 216 
This Beckman-Coulter AMH Gen II assay continues to use the antibodies of the previous DSL assay but 217 
uses native AMH in heat-inactivated bovine calf serum as a standard. The Gen II assay was calibrated to 218 
the IOT AMH ELISA, yielding a sensitivity of 0.08 ng/ml (Kumar et al., 2010). Comparison of the AMH Gen 219 
II assay with the previous assays showed that AMH values obtained with the AMH Gen II assay had a 220 
good correlation with those of the DSL assay but higher values (22-40%) were obtained with the Gen II 221 
assay (Wallace et al., 2011, Li et al., 2012). Because the AMH Gen II assay was calibrated to the IOT 222 
assay, this difference could potentially be accounted for by the previously observed difference between 223 
the DSL and IOT assays. However, Li et al also observed a 35% increase in sample value in the Gen II 224 
assay compared to the IOT assay (Li, et al., 2012). This finding is unexpected given that the AMH Gen II 225 
assay was calibrated to the IOT assay. Furthermore, there have been studies questioning the stability of 226 
AMH upon storage, sample handling and sample diluting, either prior to or by sequential addition to the 227 
microtitre plate, which all might affect serum AMH values (Rustamov et al., 2012). In contrast, stable 228 
serum AMH values were reported upon long term storage at -20°C with the previous DSL assay 229 
(Kevenaar, et al., 2006). Also with the AMH Gen II assay fairly stable values were reported for serum 230 
AMH but not for whole blood (Kumar, et al., 2010, Fleming and Nelson, 2012, Fleming, et al., 2013). 231 
Concerns about the robustness of the AMH Gen II assay have been fuelled by recent safety notices and 232 
technical update letters from Beckman-Coulter, indicating that undiluted samples may give falsely low 233 
values due to interference from complement, but also that some samples diluted prior to addition to the 234 
plate may give falsely elevated values. Therefore, results published so far with the AMH Gen II assay 235 
have to be taken with caution and will probably need to be revisited once the technical issues are 236 
resolved. Furthermore, it is recommended that these changes are validated in independent research 237 
before clinical application of the assay. Adapting clinical cut-off values from the IOT assay to the Gen II 238 
assay is not recommended, because a different antibody pair is used. Likewise, a simple conversion 239 
factor to recalculate values from the DSL assay to AMH Gen II is also not recommended, given the issues 240 
raised above. Therefore, although the clinical application of serum AMH, as discussed in this review, is 241 
not in question, it is also not recommended to compare absolute values from clinical studies that use 242 
different assays. To maximise the clinical utility of AMH measurement it is also critical to develop an 243 
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international standard for AMH that is safeguarded and distributed by a competent authority such as 244 
the National Institute for Biological Standards and Control. This would allow harmonization of current 245 
and potential new AMH assays, thereby eliminating the need to establish assay-specific normative and 246 
cut-off values.  247 
 248 
Variability of serum AMH in normal women  249 
 250 
Inter-individual variability of AMH is high, mainly due to the very high variability in the number of antral 251 
follicles within groups of subjects of similar age (Gougeon, 1998; La Marca et al., 2011; Almog et al., 252 
2011). There also seems to be ethnic variation, with African-American (Seifer et al., 2009; Schuh-Huerta 253 
et al., 2012) and Hispanic (Seifer, et al., 2009) women having lower serum AMH levels than those found 254 
in Caucasian women which may indicate a discrepancy between ovarian follicle number and AMH 255 
production. Some studies have indicated a negative relationship between BMI and AMH (Freeman et al., 256 
2007; Steiner et al., 2010) but this has not been consistent (Halawaty et al., 2010; Skalba et al., 2011, La 257 
Marca et al., 2012; Overbeek et al., 2012). In a recent study, AMH was negatively related to BMI but the 258 
relationship was age-dependent (La Marca, et al., 2012) suggesting that the relationship is secondary to 259 
the stronger relationship of the two variables with age. Contradictory result have also been reported on 260 
the relationship between smoking and AMH, with some studies reporting reduced AMH levels in 261 
smokers (Freeman, et al., 2007, Plante et al., 2010, Freour et al., 2012) and others reporting similar 262 
values (Nardo et al., 2007; Dafopoulos et al., 2010; Waylen et al., 2010; La Marca, et al., 2012).   263 
Analysis of intra-individual variability may be secondary to true biological variations in AMH levels in the 264 
circulation. The inter-menstrual cycle variability has been appropriately analyzed in two prospective 265 
studies (Fanchin et al., 2005, van Disseldorp et al., 2010), both of which concluded that 89% of the 266 
variation in AMH was due to between-subject variation, while only 11% of variability was secondary to 267 
individual fluctuation in AMH levels. Both studies found a similar intra-class coefficient (ICC) of 0.89, 268 
which is the ratio of the inter-individual variability over the total variability thus the higher the ICC, the 269 
lower the intra-individual variability. The majority of studies indicate that AMH is relatively stable 270 
through the menstrual cycle, as would be expected since the dominant follicle and corpus luteum do not 271 
secrete AMH (Hehenkamp, 2006; La Marca et al., 2006; Tsepelidis et al., 2007) (Figure 3). Van 272 
Disseldorp, et al. (2010) calculated the intra-individual CV of AMH to be 13 %, with intra-individual 273 
fluctuations within the same quintile in 72% of women and to cross two quintiles in only 1%. In contrast, 274 
a recent but small study found a reduction in circulating AMH in the luteal phase and intra-individual 275 
variance of AMH to be as high as 80% (Hadlow et al., 2013). In a prospective study based on 20 women, 276 
the authors described two different patterns for AMH dyanmics throughout the menstrual cycle. The 277 
“younger ovary” pattern had higher mean AMH and significant variations in AMH levels throughout the 278 
cycle. This was in contrast with an “aging ovary” pattern with low mean AMH, shorter menstrual cycle 279 
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lengths, and very low variation in AMH levels, suggesting diminished ovarian reserve. Fluctuations were 280 
randomly distributed during the cycle indicating that measuring on a fixed day would not be 281 
advantageous. 282 
The literature also contains contradictory reports regarding the influence of conditions associated with 283 
gonadotrophin suppression, particularly hormonal oral contraception use and pregnancy, with serum 284 
AMH level. It seems likely that weak study size and design underlies this confusion. Recently a cohort 285 
study based on 863 women (228 OC-users and 504 non-users) reported that AMH serum levels were 286 
29.8% lower in oral contraception users than controls (Bentzen et al., 2012). This has been recently 287 
confirmed by Dolleman et al. (2013). In a small but randomized trial of 42 healthy women administered 288 
oral, transdermal or vaginal ring hormonal contraception for 9 weeks, AMH levels decreased by almost 289 
50% in all treatment groups (Kallio et al., 2013). Conversely, serum AMH level increases in subsequent 290 
natural cycles after stopping with hormonal contraception (van den Berg et al., 2010). Similarly in 291 
relation to pregnancy, in the only longitudinal study available (n=60) a significant decrease in AMH levels 292 
was found in the 2nd and 3rd trimesters compared to the 1st trimester, with a mean reduction at the end 293 
of pregnancy of about 50% (Nelson et al., 2010). Such a decline in AMH levels during pregnancy has 294 
been recently confirmed by Köninger et al. (2013) in a cross-sectional study. While this no doubt reflects 295 
reduced follicular maturation, there may also be a contribution of pregnancy-associated haemodilution 296 
and increased plasma-protein binding.  297 
In conclusion, fluctuations in AMH levels have been reported for a number of conditions and this has to 298 
be taken into account when interpreting values in clinical practice. While fluctuations in the menstrual 299 
cycle appear to be random and minor hence permitting the measurement of AMH independently of the 300 
cycle phase, ovarian suppression as induced by physiological or pharmacological interventions may 301 
reduce AMH levels. Thus, serum AMH may not retain its accuracy as a predictor of the ovarian reserve in 302 
women using long-term hormonal contraception. 303 
 304 
Derivation of a normative model for AMH from conception to menopause 305 
The emerging value of AMH measurement requires understanding of its pattern across the whole 306 
female life-course. Most published studies that report AMH in normal girls and women include only a 307 
relatively small age range, thus a ‘data-driven’ approach has been used (Kelsey et al., 2012). This 308 
involved extracting data using a semi-automated procedure, and combined it with other unpublished 309 
data. The resulting combined dataset (n = 3,260; age range -0.3 years to 54 years)(Kelsey et al., 2011) 310 
forms a representative sample of AMH levels in the population of healthy female humans, and can 311 
therefore be used as a basis for a predictive model of serum AMH level with changing age and was used 312 
to generate  and validate the model.  313 
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Analysis of the model shows that the dynamics of circulating AMH levels throughout life can be split into 314 
several distinct phases (Figure 4). A peak shortly after birth confirms that girls also undergo a ‘mini 315 
puberty’ of the neonate, following which there is a sustained rise to about 9 years of age. There is an 316 
inflection with even a slight decline during the pubertal ages (9–15 years), followed by a second growth 317 
phase to a peak at an age of about 25 years. After this, there is a steady decline to undetectable levels at 318 
an average age of 50–51 years, corresponding to the menopause.  319 
When non-growing follicle (NGF) recruitment dynamics are considered and compared to AMH levels 320 
(Figure 4) there is a strong and positive correlation (r = 0.96) between declining AMH and declining 321 
numbers of recruited NGFs after age 25 (the average age of peak AMH). This observation underpins the 322 
use of serum AMH level as an indirect indicator of human ovarian reserve for ages after the mid-323 
twenties. Before the age of 25, the relationships between AMH and ovarian reserve are more complex 324 
with overall a positive relationship between rising AMH and increasing follicle growth activation, and 325 
thus we would recommend caution in the interpretation of AMH concentrations in girls and young 326 
women as an indirect indicator of ovarian reserve.  327 
Ovarian Reserve assessment 328 
Assessment of Ovarian Reserve in normal women 329 
From the ART literature, it is clear that AMH can predict the ovarian response to hyperstimulation (Broer 330 
et al., 2013). AMH is superior to female age in assessing the quantitative aspects of the ovarian reserve 331 
but its value is much more limited in the prediction of ongoing pregnancy. Indeed no combination of 332 
ovarian reserve tests (ORTs) has been able to improve the accuracy of female age in identifying those 333 
with a close to zero prognosis (Hendriks et al., 2008, Broer, et al., 2013). Qualitative aspects of the 334 
ovarian reserve are much more difficult to capture.  335 
The role for AMH as a predictor of natural fertility has been studied in a limited number of papers. In a 336 
prospective study of women mostly in their 30’s, those with low AMH had significantly reduced 337 
fecundability, after adjustment for age (Steiner, et al., 2010). In contrast, fecundability in healthy young 338 
women with no prior knowledge of their fecundity, appeared not to be compromised if very low AMH 339 
levels were present (Hagen et al., 2012). However, it must be stressed that these results were obtained 340 
with the Gen II assay that provided at that time lower measurement than it was believed (see “assay” 341 
section). Conversely, the probability of conceiving was reduced in women with high AMH levels, 342 
suggesting that this represented women with overt or mitigated conditions of anovulation. Being a 343 
quantity marker, the true value for AMH may therefore be found in predicting the timelines in the 344 
ovarian ageing process that are dictated by quantity alone. 345 
 346 
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To study the value of the ORTs in the assessment of the future ovarian reserve status, long term follow 347 
up studies are required, where several factors assessed at initiation of the follow up are linked to the 348 
final outcome age at menopause. As menopause has a fixed time relation to earlier events such as onset 349 
of cycle irregularity (average age 46 years) and the loss of natural fertility (average age 41 years), a 350 
woman’s reproductive lifespan can be predicted from forecasting age at menopause. To date, a total of 351 
four datasets are available addressing this issue. In two small studies, it has been demonstrated that 352 
across a period of 9 and 12 years, AMH level will adjust the predictions that can be based on female age 353 
at the moment of AMH sampling, so that women with low age-specific AMH will have menopause 354 
earlier and vice versa (Tehrani et al., 2009, Broer et al., 2011). A larger analysis is now available from the 355 
Iranian study (Tehrani et al., 2013). A third study confirmed these findings in a group of women of late 356 
reproductive age, but with still detectable levels of AMH (Freeman, et al., 2007). All these datasets 357 
however have very wide confidence intervals in the predictive value of a single AMH measurement. The 358 
rate of change over time may also affect the time to menopause, and be susceptible to extrinsic as well 359 
as intrinsic factors. 360 
Genetic factors have proven to play a major role in determining the variation in menopausal age, 361 
as demonstrated in several mother-daughter, twin and sib-pair studies. Next to genetic factors, several 362 
environmental and life-style factors like smoking, body mass index, use of alcohol and parity have 363 
claimed to influence menopausal timing as well. Thus, menopausal age is considered a complex genetic 364 
trait. From a recent review (Voorhuis et al., 2010), it became apparent that a number of genetic regions 365 
and variants involved in several possible pathways underlying timing of age at menopause could be 366 
identified. Regarding a potential role for AMH or its receptor in modulating the rate of follicle loss form 367 
the primordial follicle pool, it has been demonstrated in two separate studies that common variation in 368 
the AMHR2 gene modifies the relationship between parity and age at natural menopause (Kevenaar et 369 
al., 2007; Voorhuis et al., 2010). Moreover, interactions between common variation in the AMH and 370 
AMH receptor II gene in their effect on menopause have further supported a potential role for factors 371 
that steer initial follicle recruitment (Braem et al., 2013). 372 
The value of predicting age at menopause serves multiple targets. First of all, the ability to assess the 373 
future ovarian reserve status, and thereby the reproductive lifespan of an individual women, will have 374 
implications for female infertility. Because of the fixed time interval that is believed to be present, 375 
prediction of age at menopause will predict the age of natural end of fertility. If such predictions could 376 
be made early in life, with sufficient accuracy, this could have a great influence on individual women 377 
making decisions regarding career and a wish to have children. It is at present unclear whether AMH 378 
measurement meets those criteria. 379 
AMH in the assessment of ovarian damage from chemotherapy, radiotherapy and surgery.   380 
 381 
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The relationship between serum AMH and the number of small growing and indeed primordial follicles 382 
has made it a prime potential tool for the investigation of gonadotoxicity of cancer therapy and of loss 383 
of the ovarian reserve from ovarian surgery. AMH offers the possibility of a more accurate assessment, 384 
revealing partial loss of the ovarian reserve, as well as ovarian failure. It may also be of value in children 385 
where FSH and inhibin B are not useful, and in individualising the degree of damage when measured 386 
prospectively.   387 
A decrease in serum AMH was first described in women who had had childhood cancer but who still had 388 
regular menses, compared to an age matched control group (Bath et al., 2003).  In contrast there was no 389 
difference in serum FSH or inhibin B between groups.  Similar findings have been shown in breast cancer 390 
survivors (Partridge et al., 2010). AMH was decreased in a study of ovarian function in young adults 391 
following treatment for childhood Hodgkin lymphoma with a clear dose response demonstrated 392 
between the number of chemotherapy cycles and the serum AMH (van Beek et al., 2007). FSH also rose 393 
with increasing treatment, but AMH appeared to have greater sensitivity to detect ovarian damage at 394 
lower doses of chemotherapy. The gonadotoxicity of alkylating agent based protocols has been shown in 395 
a range of childhood and adult malignancies (Rosendahl et al., 2008; Lie Fong et al., 2009; Gracia et al., 396 
2012) but is most clearly demonstrated in a prospective study in young women with lymphoma 397 
(Decanter et al., 2010): AMH concentrations fell in all women during therapy but in the non-alkylating 398 
agent group there was then recovery to concentrations similar to pre-treatment whereas there was no 399 
evidence of recovery in women treated with alkylating agent based therapies. 400 
Radiotherapy is also widely recognised to cause ovarian damage even at low doses and women treated 401 
with radiotherapy that includes the pelvis (including abdominal pelvic therapy in children or total body 402 
irradiation) generally have very low or undetectable AMH concentrations (Gracia, et al., 2012) (Lie Fong, 403 
et al., 2009).  404 
Most of these studies were retrospective in nature, with no pre-treatment samples taken. There is also a 405 
dearth of data linking post treatment AMH to other clinical variables, most importantly fertility and 406 
subsequent reproductive lifespan, although a recent analysis shows a high prevalence of successful 407 
pregnancy in childhood lymphoma survivors despite low AMH concentrations (Hamre et al., 2012). A 408 
prospective study in women with newly diagnosed breast cancer linked pre-treatment AMH with long 409 
term ovarian function at 5 years (Anderson and Cameron, 2011), pre-treatment serum AMH being 410 
markedly higher in women who continued to have menses. The predictive value of AMH for post-411 
chemotherapy ovarian function has subsequently been confirmed (Anderson et al., 2013) allowing the 412 
development of prediction tools combining age and AMH (Figure 5). It therefore appears that in addition 413 
to reflecting post-chemotherapy (or radiotherapy) damage, AMH is also able to predict on-going ovarian 414 
activity after such treatment, and the existing data suggest it is likely to be more robust than either FSH 415 
or inhibin B in this regard.  Consistent with this, a study in younger women has demonstrated that 416 
pretreatment AMH predicts post-chemotherapy recovery, with a more rapid recovery in women with 417 
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higher pretreatment AMH (Dillon et al., 2013). Older women with cancer may have lowered 418 
pretreatment AMH concentrations; this was not observed in younger women (Su et al., 2013).  419 
Substantial prospective studies are required to develop a clearer analysis of the predictive value of AMH 420 
in different circumstances and it may be of value in information provision for example regarding the 421 
need for fertility preservation strategies.   422 
AMH is detectible in girls of all ages, unlike other reproductive hormones, and rises steadily through 423 
childhood thus may be of value in the assessment of ovarian function in pre-pubertal girls. In a 424 
prospective analysis of girls with varied diagnosis (and therefore undergoing differed therapies) at 425 
different ages, AMH declined during repeated chemotherapy cycles (Brougham et al., 2012).  Strikingly, 426 
in girls judged to be at medium or low risk of long-term ovarian damage, AMH recovered to 427 
concentrations similar to pre-treatment, whereas in girls judged to be at high risk, serum AMH at the 428 
end of treatment was undetectable and showed no evidence of recovery. Post-treatment AMH 429 
therefore appeared to identify even very young girls who are very likely to require pubertal induction, 430 
distinct from others who may be able to be reassured as to the likelihood of satisfactory ovarian 431 
function later in life. Long term follow up of these different groups is required to ascertain fully the value 432 
of post childhood cancer AMH in predicting long term ovarian function whether reflected in achieving 433 
spontaneous puberty, fertility or reproductive lifespan. 434 
The impact of ovarian surgery on the ovarian reserve as measured by AMH has also been investigated, 435 
and two systematic reviews of the impact of ovarian surgery for endometriosis have been published 436 
(Raffi et al., 2012; Somigliana et al., 2012). Both analyses highlight the heterogeneity of study design and 437 
the difficulty in pooling data. However both conclude that ovarian endometrioma surgery is associated 438 
with a decline in serum AMH, indicating the removal of a significant part of the ovarian reserve. A 439 
subsequent large retrospective analysis has confirmed the impact of endometrioma surgery on the 440 
ovarian reserve as detected by serum AMH (Streuli et al., 2012), and these findings should be taken in to 441 
account in the planning and decision making process relating to ovarian surgery in women desirous of 442 
future pregnancy.   443 
Assessment of Ovarian Reserve in infertility and ART patients 444 
Age and ovarian reserve are potentially the most important patient characteristics determining the 445 
success of assisted conception, with interpretation of AMH in an age-specific manner now feasible 446 
(Nelson et al., 2011a; Nelson et al., 2011c; Almog, et al., 2011). Recognition of the linear relationship of 447 
AMH with oocyte yield was a critical step forward (Nelson et al., 2007; La Marca et al., 2010). That AMH 448 
can predict ovarian response accurately (Broer et al., 2011)(Broer et al., 2009) enables clinicians to avoid 449 
iatrogenic complications and to choose the optimal stimulation strategy. This also ensures that patients 450 
are counselled appropriately with realistic expectations of the outcome of their ovarian stimulation.   451 
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At one extreme of the response spectrum we can identify women who are at risk of OHSS (Al-Inany et 452 
al., 2011, Broer, et al., 2011). We can adjust our stimulation strategy to incorporate GnRH antagonists 453 
(Al-Inany, et al., 2011) reducing the risk of this potentially fatal complication (Acolet et al., 2005, Braat et 454 
al., 2010). Choosing a GnRH antagonist prtocol and adjusting the FSH dose according to a high serum 455 
AMH level should preclude OHSS but at present, however, only locally-derived thresholds can be used 456 
since there is no consensus on an universal threshold (Broer, et al., 2011). This approach has particular 457 
benefits for women undergoing altruistic oocyte donation, removing much of the integral risk of IVF 458 
(Bodri et al., 2009).  Conversely maximising follicular recruitment would seem appropriate if a poor 459 
response was anticipated, although the optimal strategy for the poor responder remains debated 460 
(Ferraretti et al., 2011). At present the value of a mixed strategy in an ART programme has yet to be fully 461 
elucidated, but for centres where agonist strategies still dominate the advantage of an AMH-based 462 
approach over conventional dose adjustment and long course agonist for all has been demonstrated 463 
(Nelson et al., 2009). 464 
The ability to predict a very poor response has resulted in some centres withholding the first treatment 465 
cycle if a very low AMH is detected, with an overall improvement in results of the programme and 466 
substantial cost savings (Yates et al., 2011). However even women with AMH concentrations at the limit 467 
of assay sensitivity have a significant chance of conception through IVF, thus this approach appears 468 
unjustified (Anderson et al., 2012). Inevitably this chance will be lower than for a woman of the same 469 
age with a higher ovarian reserve (La Marca, et al., 2010) but to withhold treatment and not actually 470 
confirm a predicted poor response at present purely based on an AMH would seem inappropriate. This 471 
is particularly the case as this approach has not been incorporated into cost-effectiveness models with 472 
other more accurate population level models available (Lawlor and Nelson, 2012; Nelson and Lawlor, 473 
2011).  474 
Whether knowing the anticipated oocyte response has a beneficial psychological effect for the couple 475 
and thereby reduces cycle drop out has not been formally evaluated. Discussion of the ovarian 476 
assessment report may set patient’s expectations appropriately particularly at the bottom end of the 477 
spectrum where only a few oocytes may be retrieved. Given that many women do not fully appreciate 478 
the detrimental effect of age on oocyte number, the ability to guide them on overall success using a 479 
combination of their age as a surrogate for oocyte quality, and AMH for oocyte yield is a powerful tool 480 
(La Marca et al., 2011).   481 
It is likely in the future that with standardisation of AMH measurement and stimulation strategies, 482 
multivariate prediction models with tight confidence intervals will be able to be created and 483 
individualised reports generated. Steps on this path have already been made with optimal prediction of 484 
excessive response achieved by combining age, AMH and antral follicle count (Broer et al., 2011a) and 485 
refinement of gonadotropin dosing by combining AMH with FSH and age (La Marca et al., 2012). The 486 
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future is therefore likely to harness the collective power of biomarkers including AMH to ensure true 487 
personalisation of ovarian stimulation. 488 
 489 
Factors influencing the relationship between and the predictability of AMH and antral follicle count 490 
(AFC)  491 
The follicular pool that influences serum AMH levels the most probably is that of 1-2 mm follicles, 492 
although some analyses have suggested a slightly larger size (Jeppesen, et al., 2013) (see section 3-1). 493 
This notion assumes a particular importance not only when we analyze the strength of the relationship 494 
between the ultrasonographic counting of antral follicles (AFC) and serum AMH levels but also when we 495 
compare the clinical predictability of both parameters.  496 
Although the positive relationship between AFC and serum AMH levels has been recognized for over ten 497 
years (Fanchin et al., 2003), cases of discrepancy are sporadically observed (Schipper et al., 2012). These 498 
cases may result, at least in part, from technical difficulties but other physiological contingencies may 499 
influence this expected relationship. According to recent guidelines (Broekmans et al., 2010) and current 500 
clinical practice worldwide, ultrasonographic counting considers antral follicles whose diameter varies 501 
considerably, from 2 to 10 mm. It is also noteworthy that ultrasound technology cannot distinguish 502 
healthy from atretic follicles. Therefore, the strength of the correlation between AFC and serum AMH is 503 
influenced by at least 2 additional factors. The first is antral follicle sizes. It is likely that a patient whose 504 
AFC is mostly represented by small follicles (1-2mm) will display higher serum AMH levels than a patient 505 
who has a majority of large antral follicles (>6 mm). The second factor is follicle “health“ as granulosa 506 
cell atresia may hinder AMH production. Further clinical studies are needed to confirm these 507 
hypotheses. 508 
In line with this, both AMH and AFC have been shown to be useful markers of the ovarian response to 509 
controlled ovarian hyperstimulation (Broer, et al., 2013). Again here, two other refinements should be 510 
brought to this clinical observation. On the one hand, it is probable that, in the beginning of the follicular 511 
phase, it is the large antral follicles that will respond first to gonadotropin treatment. As these follicles 512 
are already losing their ability to produce AMH, AFC might better predict ovarian response than AMH 513 
(Mutlu et al., 2013). On the other hand, if we consider that atretic antral follicles will not properly 514 
respond to exogenous FSH, AMH should be the most reliable marker as it is not produced by atretic 515 
follicles that still are counted by ultrasound. Another pertinent issue regarding both biomarkers is that, 516 
contrary to AFC, AMH is also an important regulator of ovarian function, as discussed above. In the 517 
ovary, AMH exerts an inhibiting role on many follicular functions, including granulosa cell sensitivity to 518 
FSH. In support of this, antral follicle responsiveness to exogenous gonadotropins, clinically assessed by 519 
the Follicle Output RaTe (FORT), is inversely correlated with serum AMH (Genro et al., 2011). 520 
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Therefore, from a clinical standpoint, both AMH and AFC provide the physician with useful information 521 
regarding ovarian follicular status and responsiveness to controlled ovarian hyperstimulation. While 522 
AMH provides information essentially on the number of very small, non-atretic follicles, AFC is 523 
contributive to detect follicle sizes and evaluate size discrepancies, with both analyses being 524 
complementary to the proper adaptation of the type of stimulation required by the patient. 525 
Polycystic Ovary Syndrome (PCOS) 526 
AMH and its putative role in PCOS pathophysiology 527 
PCOS, a heterogeneous condition, is the most prevalent endocrine disorder in women, affecting 5 to 528 
10% of the female population (Franks, 2008).  Women with PCOS present with a range of symptoms 529 
such as acne, hirsutism and/or menstrual irregularities and have an increased risk of type II diabetes. 530 
The condition imposes a considerable economic burden on health systems internationally (Azziz et al., 531 
2005). Polycystic ovaries (PCOs) are characterised by an increase in the number of follicles at all growing 532 
stages (Hughesdon, 1982; Webber et al., 2003; Maciel et al., 2004). PCOS is almost certainly a genetic 533 
condition (Kosova and Urbanek, 2013), but the cause of the change in ovarian and the cause of 534 
anovulation which affects a subgroup of these women remains unknown. 535 
The ability of AMH to alter early follicle growth was demonstrated by the AMH knock-out mouse model 536 
(Durlinger, et al., 1999, Durlinger, et al., 2002) in which there is an increase in the initiation of primordial 537 
follicles into the growing pool (see section 3). This morphology appeared similar to that seen in 538 
polycystic ovaries (PCOs) and so an assessment of the production of AMH by PCOs was carried out. 539 
Stubbs et al., 2005 found fewer primordial and transitional follicles positively stained for AMH from 540 
anovulatory PCO than in normal ovaries. Reduced AMH in anovulatory PCO might enhance the transition 541 
of follicles to the growing phases, or might be a marker of abnormal early follicle growth in PCOS.   542 
Serum AMH is two to four-fold higher in women with PCOS than in normal women (Pigny et al., 2003; 543 
Laven et al., 2004; Park et al., 2010; Lie Fong et al., 2011). This increase in serum AMH was thought to 544 
reflect the increased number of small antral follicles in which AMH production is highest. However, 545 
when production of AMH per granulosa cell was compared between normal ovaries, ovulatory and 546 
anovulatory PCOs (Pellatt et al., 2007), AMH production was on average 75 times higher per granulosa 547 
cell from anovulatory PCOs and 20 times higher from ovulatory PCOs. This indicates that the increase in 548 
AMH is due to an intrinsic property of granulosa cells in PCOs, a property that persists even after 549 
stimulation for IVF (Catteau-Jonard et al., 2008). These increased concentrations are also found in 550 
follicular fluid (Das et al., 2008).  551 
The cause of such high levels of AMH in antral follicles in PCOS is currently unknown. However there is 552 
evidence to support a role for androgens as a positive correlation with AMH in serum has been reported 553 
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(Carlsen et al., 2009; Pigny, et al., 2003; Laven, et al., 2004; Eldar-Geva et al., 2005), and over-production 554 
of androgens is an intrinsic defect of theca from PCOs (Gilling-Smith et al., 1994). It is curious that AMH 555 
should be lower in preantral follicles and then higher once the follicle reaches the antral stage, however 556 
prenatal testosterone treatment of sheep produced precisely this effect (Veiga-Lopez et al., 2011). In 557 
vitro however, androgens have not been shown to do this and indeed androgens have been shown to 558 
reduce antral follicle granulosa cell AMH production in a bovine model (Crisosto et al., 2009). In human, 559 
serum AMH levels decrease in female to male transsexual women using testosterone as cross-sex 560 
therapy (Caanen M et al., 2013). Other groups have demonstrated inhibition of AMH production by 561 
gonadotrophins, particularly FSH (Baarends et al., 1995; Panidis et al., 2011). Others found no such 562 
inhibitory effect on granulosa cells from normal ovaries; in contrast, FSH did inhibit AMH production in 563 
cultured granulosa cells from polycystic ovaries (Pellatt, et al., 2007) whereas LH significantly stimulated 564 
production. 565 
Although many aspects of AMH action in the ovary remain to be elucidated, knowledge is emerging. 566 
AMH significantly decreases FSH- and LH- induced aromatase expression in granulosa cells as well as 567 
reducing the activity of the ovary-specific aromatase promoter II (see section 3).  This results in a 568 
significant reduction in estradiol production (Pellatt et al., 2011). AMH also inhibits FSH-stimulated FSH 569 
receptor mRNA expression (Pellatt, et al., 2011). The fact that AMH is inhibitory of factors required for 570 
follicle growth adds considerable significance to the finding of high AMH in PCOS. LH reduces AMHRII 571 
expression in granulosa luteal cells collected from women with normal ovaries and ovulatory PCOS, but 572 
was unable to do so in women with anovulatory PCOS (Pierre et al., 2013). It can be envisaged that AMH 573 
content in antral follicles in these ovaries would be sufficient to inhibit FSH-stimulated aromatase 574 
expression and would thus prevent the inhibitory effect of estradiol on AMH production (Figure 1). This 575 
effect would be amplified by the loss of LH-induced down-regulation of AMHRII expression in women 576 
with anovulatory PCOS. These findings suggest that AMH may contribute to anovulation in PCOS. In 577 
agreement, it has been shown that emergence of a dominant follicle in anovulatory women with PCOS 578 
under recFSH is preceded by a significant reduction in serum AMH level (Catteau-Jonard et al., 2007).  579 
AMH in diagnosing PCOS: a shift from ultrasound to laboratory  580 
Given its strong involvement in the pathophysiology of PCOS (see section 5.1), serum AMH is a subject 581 
of special interest for clinicians involved in this field. There is considerable interest in whether it might 582 
become part of the diagnostic criteria for the condition, although this is at present premature. It may 583 
also shed light on different subtypes of this diverse condition leading to greater understanding of the 584 
disordered follicle growth. Certainly, the serum AMH concentration appears to be greatly increased in 585 
most patients with PCOS (Pigny, et al., 2003, Laven, et al., 2004, Li et al., 2011). This elevation is highly 586 
pertinent as it has been shown that polycystic ovaries (PCO) exhibit an increased number of AMH-587 
producing pre-antral and small antral follicles, the latter expressing the most AMH (Weenen, et al., 588 
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2004) and contributing the most to the circulating AMH (Jeppesen, et al., 2013). In addition, production 589 
of AMH is greatly increased in GC from PCO, especially if the patient is oligo-anovulatory, as discussed 590 
above (Pellatt, et al., 2010). Therefore, not surprisingly, many authors have reported a strong correlation 591 
between plasma levels of AMH and follicle count on ultrasound in PCOS patients. The strength of this 592 
relationship is even greater with newer ultrasound technology allowing the counting of 1-2 mm follicles 593 
(Dewailly et al., 2011).  594 
The strong association between AMH and follicle count has led some authors to compare the 595 
performance of one against the other for the diagnosis of PCOS. However, the results in the current 596 
literature are not homogeneous between studies, as well demonstrated in a recent compilation 597 
(Iliodromiti et al., 2013). Part of this heterogeneity is due to the lack of well-defined populations. In 598 
particular, it must be stressed that many authors have used the threshold for follicle excess that was 599 
established in 2003 at the Rotterdam Consensus Conference to define PCOM (Balen et al., 2003), namely 600 
12 follicles of 2-9 mm diameter per ovary. With the latest generation of ultrasound equipment and using 601 
well-defined populations, recent studies have proposed to increase this threshold to 19 or 25 (Dewailly, 602 
et al., 2011, Lujan et al., 2013, respectively). This threshold will probably continue to evolve in parallel 603 
with the technical improvement of ultrasound equipment. 604 
Beside the flaw in the ultrasound definition of controls and patients, the variability of the results can 605 
also be explained by the problem that prevails with serum AMH assays. About half of the previous 606 
studies were performed using either the DSL or IOT assays (Iliodromiti, et al., 2013), for which 607 
concordance in the values is problematic (see above). More recent studies using the Gen II kit should 608 
also be interpreted with caution (see above).  609 
It is therefore impossible to date to propose a consensual and universal diagnostic threshold for serum 610 
AMH that is predictive of PCOS. Using the IOT assay, serum AMH was found to be more efficient than 611 
the follicle count with excellent sensitivity and specificity for a threshold of 35 pmol/l (4.9 ng/ml) 612 
(Dewailly, et al., 2011). Contrary to other studies, specific thresholds for AMH and follicle count were 613 
calculated without using pre-determined values. In addition, women with supposedly asymptomatic 614 
PCOM were excluded from the control group of regularly menstruating women by cluster analysis. If 615 
these results can be replicated with the new AMH assays, serum AMH may become an accurate and 616 
reliable marker that may eventually replace the follicle count which itself, in turn, suffers from great 617 
controversy in the current literature. It is reasonable to propose that the increased serum AMH is a 618 
surrogate to the term "PCOM" in the Rotterdam classification (Rotterdam ESHRE/ASRM-sponsored PCOS 619 
consensus workshop group, 2004). Further, since we have now at our disposal two different markers, 620 
one being morphological (PCOM) and the other being biochemical (increased serum AMH), the terms 621 
“PCO-like abnormalities” (PCO-L) may become more accepted as the third item of the Rotterdam 622 
classification (Robin et al., 2012). 623 
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In addition, the serum AMH correlates with the severity of PCOS and precisely with the severity of both 624 
hyperandrogenism (Piouka et al., 2009) and oligo-anovulation (Laven, et al., 2004, Catteau-Jonard et 625 
al., 2012). By principal component analysis, it has been shown that a high serum AMH level can be 626 
considered a marker of hyperandrogenism and may therefore also be considered as a replacement for 627 
this other item in the Rotterdam classification (Dewailly et al., 2010). This would reconcile the different 628 
classifications currently available for the diagnosis of PCOS since some of them necessarily require the 629 
presence of hyperandrogenism to retain the diagnosis (Azziz et al., 2009). The only exception to this 630 
assertion would be the presence of PCOS in women with type 1 diabetes, where serum AMH does not 631 
correlate to androgen levels (Codner et al., 2007).  632 
Therefore, to establish the diagnosis of PCOS, after exclusion of other diagnoses, oligo-anovulation and 633 
HA should first be required. In the cases where one is missing, then “PCO-L” (i.e., high AFC and/or serum 634 
AMH level) could be used as a surrogate for either oligo-anovulation or HA. It must be stressed, 635 
however, that the thresholds for an excessive AFC and serum AMH level have to be revisited and 636 
validated worldwide in populations of different ethnicity. Meanwhile, local in-house control data can be 637 
used. We think this information is important and useful for diagnostic concerns as well as for 638 
phenotype/genotype analysis within genetic studies.  639 
The diagnostic value of serum AMH concentrations has also been studied in adolescents since 640 
ultrasound is often unreliable in detecting PCOM in this population. A study in Chilean adolescents 641 
identified a cut-off serum AMH concentration of 60 pmol/l (with the IOT assay) to diagnose PCOM in 642 
regularly menstruating adolescents, with a sensitivity and specificity of 64% and 90% (area under the 643 
ROC curve = 0.87) (Villarroel et al., 2011). The results were not as good in Australian adolescents with 644 
the same assay (area under the ROC curve = 0.67) leading the authors to conclude that serum AMH was 645 
a questionable surrogate for PCOM in adolescents (Hart et al., 2010). 646 
Finally, in addition to its diagnostic role, the determination of AMH could be used in the future to 647 
establish treatment protocols, and in particular to define the strategy for the induction of ovulation in 648 
infertile oligo-anovulatory PCOS women. To date, there are very few studies that have examined the 649 
predictive power of AMH assay for response to clomifene, recombinant FSH or to ovarian drilling. 650 
Similarly, AMH is of value as a good predictor of the risk of ovarian hyperstimulation in an IVF setting 651 
(Broer, et al., 2011) .  652 
The current technical difficulties with the determination of serum AMH may have dampened the 653 
enthusiasm of some clinicians for this marker of PCOM. However there are sufficient data to support the 654 
view that this assay may replace (or be an alternative for) AFC in the Rotterdam classification, which will 655 
make it even more reliable and more flexible, especially in situations when ultrasound is uninformative 656 
or impossible, as in obese women or adolescents. 657 
 658 
Future avenues 659 
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Recent years have shown multiple ways in which AMH is not only a “male” hormone but is emerging as 660 
an invaluable tool offering new insights into ovarian function in childhood, adolescence and through the 661 
reproductive years. Although knowledge of its precise roles in ovarian physiology still requires extensive 662 
fundamental and clinical studies, it is already clear that AMH is crucial in maintaining the right tempo of 663 
folliculogenesis in the ovary (although there are only very limited human data), making it one of the 664 
most important ovarian hormones and one of the most crucial factors underpinning female fertility. 665 
Whether its action is exclusively intra-ovarian, within and between follicles, is a challenging issue for 666 
future research. We should think about possible endocrine effects of this hormone, possibly in ovary-to-667 
ovary interaction or in hypothalamic-pituitary-ovarian integration.  668 
At the current time, the clinical use of serum AMH assay is hampered by technical issues undermining its 669 
reliability. It is likely that these issues will be rapidly solved and the advent of more sensitive assays may 670 
confirm that serum AMH level is the best biochemical marker of ovarian function in a large array of 671 
clinical situations, both in childhood and adulthood. For the first time in female reproductive biology, we 672 
have at our disposition an easy measure of the submerged part of the iceberg of follicle growth, i.e., the 673 
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Legends to figures 1192 
 1193 
Figure 1: Schematic model of anti-Müllerian hormone (AMH) actions in the ovary.  1194 
AMH, produced by the granulosa cells of small growing follicles, inhibits initial follicle recruitment and 1195 
FSH-dependent growth and selection of preantral and small antral follicles. In addition, AMH remains 1196 
highly expressed in cumulus cells of mature follicles. The inset shows in more detail the inhibitory effect 1197 
of AMH on FSH-induced CYP19a1 expression leading to reduced E2 levels, and the inhibitory effect of E2 1198 
itself on AMH expression. AMH, anti-Müllerian hormone; FSH, follicle stimulating hormone; T, 1199 
testosterone; E2, estradiol; Cyp19a1, aromatase. Figure modified from van Houten et al. (2010). 1200 
 1201 
Figure 2: Schematic presentation depicting the processing of AMH.  1202 
AMH is produced as a precursor protein consisting of disulphide-linked monomers. Upon cleavage by 1203 
prohormone convertases the protein is cleaved into pro- and mature homodimers, which remain non-1204 
covalently associated. AMH enzyme-linked immunosorbent assays (ELISA) have been developed to 1205 
detect AMH in circulation. The regions that are recognized by the monoclonal antibodies used in the 1206 
ultrasensitive IOT assay and the Gen II assay (previously DSL) are indicated. For the Gen II assay, the 1207 
capture antibody recognized the mature region and the detector antibody recognizes the proregion.  1208 
 1209 
Figure 3: AMH variability throughout the menstrual cycle. Serum AMH appears to be stable.  1210 
(Reproduced with permission from (a) La Marca et al., 2006, (b) Hehenkamp et al., 2006 and (c) 1211 
Tsepelidis et al., 2007). 1212 
 1213 
Figure 4: AMH and follicular recruitment profile across the lifespan. 1214 
Comparison of serum AMH concentrations with NGF recruitment rates.  The red line is the log-1215 
unadjusted validated AMH model (Kelsey et al., 2011), peaking at 24.5 years.  The blue line denotes the 1216 
numbers of NGFs recruited per month towards the maturation population (Wallace and Kelsey, 2010), 1217 
with peak numbers lost at age 14.2 years on average.  Correlation coefficients (r) are given for AMH 1218 
concentrations against follicular recruitment for each developmental phase; from birth to puberty (age 9 1219 
years), during puberty (9 – 15 years), post-puberty (15- 25 years) and mature adults (>25 years).  1220 
 1221 
Figure 5: Classification mosaic chart for ongoing menses (M) or chemotherapy-related amenorrhea (A) 1222 
using pre-chemotherapy serum AMH and chronological age as predictor variables, in women with 1223 
early breast cancer.  1224 
The primary cutoff values are both for AMH, with below 3·8 pmol/L predicting amenorrhea and above 1225 
20·3 pmol/L predicting ongoing menses. Between these AMH levels there is an age threshold at 38·6 1226 
years, above which amenorrhea is predicted and below which ongoing menses are predicted. The 1227 
 33 
classification schema has sensitivity 98·2% and specificity 80·0%. Reprinted with permission from 1228 
Anderson et al 2013, Eur J Cancer. 1229 
 1230 
Figure 6: rationale for the use of serum AMH assay as a probe for PCOM 1231 
(A) All growing follicles secrete AMH but serum AMH reflects only the secretion from bigger follicles that 1232 
are in contact with the vascular bed. As the numbers of follicles in all growth stages are strongly related 1233 
to each other, serum AMH is considered to reflect the sum of growing follicles but not the number of 1234 
primordial follicles that do not secrete AMH (see section 3-1).   1235 
(B) In PCO, the numbers of all growing follicles is increased, resulting in a marked increase in serum AMH 1236 
level (see section 5). This marker may be considered as a deeper and more sensitive probe to define 1237 
follicle excess than the follicle count by ultrasound (U/S) since it appraises more follicle classes (blue 1238 
arrows). 1239 
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